pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Radical Numerics aims to develop general biological intelligence, says CEO Eric Nguyen

Oct 14, 2026·read at STAT ↗Positive

STAT’s AI Prognosis newsletter features an interview with Eric Nguyen, chief executive of Radical Numerics. The Boston-based startup says it is working toward what it calls “general biological intelligence,” a platform that could understand and model biological systems across many domains.

Nguyen describes the ambition as building a flexible AI that can learn from diverse biological data, rather than being limited to a single disease or target. He believes this broader capability could accelerate drug discovery and improve health research.

The article appears in the October 14, 2026 edition of the newsletter, which also promotes the opening day of the STAT Summit in Boston and lists upcoming sessions on AI’s promises and pitfalls.

Access to the full interview is limited to STAT+ subscribers, who receive additional analysis and event discounts.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: The startup chasing ‘general biological intelligence’”

read at STAT ↗
480 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: FDA adcomm members’ ties to industry under scrutinySTAT
  • 2h agoSTAT+: Pharmalittle: We’re reading about Sanofi settling an EU antitrust probe, ‘pharma bro’ Shkreli, and moreSTAT
  • 3h agoSTAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccineSTAT
  • 4h agoNew study examines GLP-1 impact on interactions with criminal justice system, employment, housing stabilitySTAT
  • 7h agoOpinion: We think a baby’s gut microbiome could be key to lifelong brain healthSTAT